^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

Published date:
09/11/2014
Excerpt:
We examined the functional effects of fusion proteins and the efficacy of tyrosine kinase inhibitors in mouse pre-B cells and xenografts of human Ph-like ALL....Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB fusions were sensitive in vitro to dasatinib, EPOR and JAK2 rearrangements were sensitive to ruxolitinib, and the ETV6–NTRK3 fusion was sensitive to crizotinib.
DOI:
10.1056/NEJMoa1403088
Evidence Level:
Sensitive: D – Preclinical
Title:

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

Published date:
09/11/2014
Excerpt:
...cells expressing ETV6–NTRK3 responded to the ALK inhibitor crizotinib (Fig. S17B in Supplementary Appendix 2)….
DOI:
https://dx.doi.org/10.1056%2FNEJMoa1403088